logo

For the Inventor, By the Inventor

Ingelheim am Rhein, Germany

Boehringer Ingelheim International Gmbh


USPTO Granted Patents = 1,537



Trademarks = 397

Forward Citations = 12,510

Loading Chart...
Loading Chart...

1,822 inventors (with patents filed for the assignee):

goldMedal Frank Himmelsbach (105 out of 173 patents)

silverMedal Matthias Eckhardt (93 out of 108 patents)

bronzeMedal Christoph Hoenke (54 out of 69 patents)

4.  Klaus Rudolf (51 out of 87 patents)

5.  Georg Dahmann (50 out of 58 patents)

6.  Leo Thomas (49 out of 60 patents)

7.  Elke Langkopf (49 out of 72 patents)

8.  Stefan Peters (47 out of 49 patents)

9.  Matthias Grauert (47 out of 74 patents)

10.  Riccardo Giovannini (44 out of 63 patents)

11.  Niklas Heine (42 out of 43 patents)

12.  Henri Doods (41 out of 76 patents)

13.  Doris Riether (39 out of 49 patents)

14.  Matthias Hoffmann (39 out of 50 patents)

15.  Gerhard Schaenzle (36 out of 37 patents)


Core Competencies:
Drug Metabolism
Plasma Kallikrein Inhibitors
Inflammatory Diseases
cGAS Inhibitors
Viral Inactivation
Bioreactor Technology
MDM2-P53 Inhibitors
Glucagon Analogues
DPP-4 Inhibitors
TRPC5 Modulators
Proteolysis Targeting Chimera
Multi-Specific Binding Proteins

1,537 patents:

1. 12509655 - Integrated and continuous recombinant protein manufacturing (2025-12-30),
2. 12497401 - Substituted tetrazoles as TRPA1 inhibitors (2025-12-16),
3. 12487235 - Compositions and methods for studying drug metabolism (2025-12-02),
4. 12479827 - Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors (2025-11-25),
5. 12453749 - Recombinant rhabdovirus encoding for CCL21 (2025-10-28),
6. 12448456 - Method for producing spesolimab (2025-10-21),
7. 12441785 - Methods of treating inflammatory diseases (2025-10-14),
8. 12435303 - Continuous flow reactor for low pH viral inactivation (2025-10-07),
9. 12433906 - Pharmaceutical composition, methods for treating and uses thereof (2025-10-07),
10. 12433897 - Pyridine derivatives with n-linked cyclic substituents as cGAS inhibitors (2025-10-07),
11. 12427162 - Pharmaceutical composition, methods for treating and uses thereof (2025-09-30),
12. 12427161 - Methods for treating and pharmaceutical compositions (2025-09-30),
13. RE50594 - Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors (2025-09-23),
14. 12421218 - Substituted pyrazine-carboxamide derivatives (2025-09-23),
15. 12415980 - Method for membrane gas transfer in high density bioreactor culture (2025-09-16),
Boehringer Ingelheim International GmbH is a global pharmaceutical company specializing in research, development, and manufacturing of innovative medicines. With headquarters in Ingelheim, Germany, the company operates in multiple therapeutic areas such as respiratory diseases, cardiovascular disorders, central nervous system disorders, immunology, and oncology. Boehringer Ingelheim is committed to improving human and animal health worldwide through breakthrough therapies and cutting-edge research.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

...
1,537 Patents

#1 in Ingelheim am Rhein

#33 in Germany

#632 in the World

...
Ingelheim am Rhein, Germany

Boehringer Ingelheim International Gmbh

Forward Citations = 12,510

1,822 inventors:

goldMedal Frank Himmelsbach (105 out of 173 patents)

silverMedal Matthias Eckhardt (93 out of 108 patents)

bronzeMedal Christoph Hoenke (54 out of 69 patents)

4.  Klaus Rudolf (51 out of 87 patents)

5.  Georg Dahmann (50 out of 58 patents)

Please report any incorrect information to support@idiyas.com
Loading…